SABCS 2023 Insights: "5-Year Outcomes of the IDEA Trial - ET Without RT After Breast-Conserving Surgery for Postmenopausal Patients Age 50-69 With Genomically-Selected Favorable Stage I BC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

SABCS 2023 Insights: "5-Year Outcomes of the IDEA Trial - ET Without RT After Breast-Conserving Surgery for Postmenopausal Patients Age 50-69 With Genomically-Selected Favorable Stage I BC"

By Insights from 2023 SABCS FEATURING Reshma Jagsi

493 views

December 21, 2023

0 Comments

London Breast Meeting 2024

Wed, Sep 4, 2024

11:31

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino

17:39

Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin

14:16

Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino

17:20

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino

11:28

Insights from 2023 SABCS

SABCS 2023 Insights: "ctDNA Monitoring of ER+/HER2- High Risk B…

Feat. L. Pusztai

04:28

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …

Feat. S. Tolaney

49:07

SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo

50:59

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Early Stage Breast Cancer"

Feat. S. Tolaney, H. Rugo

23:58

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri

14:59

Insights from 2023 SABCS

SABCS 2023 Insights: "NRG Oncology/NSABP B-51/RTOG 1304 Trial -…

Feat. T. Mamounas

21:37

Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons

53:42

PleXus Communications

Managing Women's Health in Menopause: Evolving Approaches for t…

Feat. J. Simon, T. Iyer, A. Fiffick, M. Minkin

08:41

Insights from 2023 SABCS

SABCS 2023 Insights: "Analysis of ctDNA for the Detection of MR…

Feat. W. Janni

18:49

Yale School of Medicine

Menopause and Hot Flashes: What Medications are Available?

Feat. M. Minkin

02:35

Integrity Continuing Education

SABCS 2023 Summary: "monarchE & NATALEE Trials - Adjuvant T…

Feat. A. Bardia

29:44

Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Optimal Duration of Endocrine Therapy for Breast Cancer

Feat. V. Kaklamani

09:41

Insights from 2023 SABCS

SABCS 2023 Insights: "ADAPTcycle Trial - Impact of Age and Ovar…

Feat. O. Gluz

03:05

ecancer

ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…

Feat. D. Slamon

09:14

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "Omission of Breast Surgery After Neoadjuva…

Feat. H. Kuerer

13:17

Jennifer Sass

Login

Login

Join VuMedi

SABCS 2023 Insights: "5-Year Outcomes of the IDEA Trial - ET Without RT After Breast-Conserving Surgery for Postmenopausal Patients Age 50-69 With Genomically-Selected Favorable Stage I BC"

Related Content